Caregiving burden and depression in family caregivers have been investigated, but little is known about how they affect paid caregivers. The aim of this study was to investigate caregiving burden and depression in paid caregivers of hospitalized patients. A cross-sectional survey study was conducted in a tertiary referral hospital (Chengdu, China) that enrolled 108 paid caregivers who worked in the inpatient department. The Caregiver Burden Inventory (CBI) and the Center for Epidemiologic Studies Depression (CES-D) scale were incorporated into a self-developed questionnaire to gather demographic information on the following four aspects: general, work, income, and family. The mean total CBI score was 29.7 ± 12.5. The time-dependence burden had the highest score of 15.3 ± 4.0, which was followed by the physical burden score of 6.5 ± 4.6, developmental burden score of 3.7 ± 4.0, social burden score of 3.2 ± 4.0, and emotional burden score of 2.4 ± 3.1. Multiple linear regression analysis showed that a higher CBI was associated with a longer time as a paid caregiver [β=7.041, 95% Confidence Interval (CI):1.935 to 12.974, p = 0.009], lower income satisfaction (β= − 6.573, 95% CI: -11.248 to −3.020, p = 0.001), and higher frequency of meeting with their relatives (β=7.125, 95% CI: 2.019 to 12.456, p = 0.006). The mean CES-D score was 11.9 ± 8.7, and significant depression was found in 28 (25.9%) paid caregivers according to the CES-D score ≥ 16 cut-off. There was a moderate positive correlation between the CBI and CES-D scores (Pearson’s r = 0.452, p < 0.001). A high caregiving burden was commonly observed in paid caregivers of hospitalized patients in China, as was a high prevalence of depression symptoms. Several associated factors were identified that could be areas for future interventions.

Background: This study aims to identify biomarkers associated with radiation-induced coronary heart disease (RICHD) in breast cancer patients by integrating bioinformatics approaches with single-cell sequencing data, providing potential therapeutic targets for RICHD treatment. Materials and Methods: Gene expression profiles associated with coronary heart disease were sourced from the Gene Expression ...

Background: The clinical value of B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided therapy for improving outcomes in patients with heart failure (HF) remains controversial. Thus, this meta-analysis synthesizes the available evidence from randomized controlled trials (RCTs) to determine whether a biomarker-guided strategy reduces all-cause mortality and HF-related hospitalizations compared with clinically guided management. Methods: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We conducted a systematic search of PubMed, Embase, the Cochrane Library, and Web of Science databases from inception to May 2025 for RCTs comparing biomarker-guided versus clinically guided management in patients with HF. Pooled risk ratios (RRs) were calculated using a random-effects model. We performed extensive supplementary analyses, including a subgroup analysis, sensitivity analysis, and trial sequential analysis (TSA). Results: We included 17 articles (reporting on 17 distinct RCTs) comprising 5069 patients. The primary meta-analysis showed that biomarker-guided therapy was associated with a significant reduction in all-cause mortality (RR 0.84, 95% confidence interval (CI) 0.73–0.96; I2 = 12.2%) and HF-related hospitalizations (RR 0.79, 95% CI 0.65–0.96; I2 = 53.7%). However, the robustness of these findings was undermined by subsequent analyses. Meanwhile, a sensitivity analysis restricted to studies with a low risk of bias rendered the mortality benefit non-significant (RR 0.90, 95% CI 0.79–1.03). Egger's test indicated potential publication bias (p = 0.0285), and TSA suggested the cumulative evidence was insufficient to draw a definitive conclusion. Conclusions: Although there is a trend toward benefit, the existing evidence for biomarker-guided HF therapy is deemed “very low” quality based on the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment. The results were compromised by methodological deficiencies in primary studies and potential publication bias. Therefore, the evidence is inadequate to support the routine use of this strategy in clinical practice. Further large-scale, high-quality RCTs are warranted. The PROSPERO Registration: CRD420250652134, https://www.crd.york.ac.uk/PROSPERO/view/CRD420250652134.

Purpose: The aim of the study was to evaluate the status of readiness for hospital discharge of pancreatic cancer patients and analysis the possible influencing factors. Methods: A total of 127 pancreatic cancer patients were surveyed from a large public hospital in China from September 2021 to February 2022.The demographic and clinical characteristics of the patients were surveyed by a self-designed questionnaire. Three internationally accepted mature scales were used to measure the scores of readiness for hospital discharge (RHD), quality of discharge teaching (QDT) and general self-efficacy (GSE). Results: The total score of RHD was 144.52±40.59, which was at a moderate level. whether discharge to rehabilitation institution or not, whether carry tube or not had difference between groups. And the total score of RHD was positively associated with the score of QDT (r = 0.62, P<0.001), GSE (r = 0.58, P<0.001). Then multivariate regression analysis found that three factors associated with RHD: QDT, GSE, and carrying tube. Conclusion: Pancreatic cancer patients’ readiness for hospital discharge was dissatisfactory, and we need to optimize health education, improve their self-efficacy, pay more attention to the patients discharge with tubes.